MX2019013714A - Metodos de tratamiento. - Google Patents

Metodos de tratamiento.

Info

Publication number
MX2019013714A
MX2019013714A MX2019013714A MX2019013714A MX2019013714A MX 2019013714 A MX2019013714 A MX 2019013714A MX 2019013714 A MX2019013714 A MX 2019013714A MX 2019013714 A MX2019013714 A MX 2019013714A MX 2019013714 A MX2019013714 A MX 2019013714A
Authority
MX
Mexico
Prior art keywords
posaconazole
substrate drug
patient
treated
cyp3a4 substrate
Prior art date
Application number
MX2019013714A
Other languages
English (en)
Spanish (es)
Inventor
Christina Chow
Sundar Srinivasan
Original Assignee
Bow River LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bow River LLC filed Critical Bow River LLC
Publication of MX2019013714A publication Critical patent/MX2019013714A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
MX2019013714A 2017-05-16 2017-05-16 Metodos de tratamiento. MX2019013714A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/596,585 US10376507B2 (en) 2017-05-16 2017-05-16 Method of treating a patient with a CYP3A4 substrate drug
PCT/US2017/032924 WO2018212764A1 (en) 2017-05-16 2017-05-16 Methods of treatment

Publications (1)

Publication Number Publication Date
MX2019013714A true MX2019013714A (es) 2020-07-14

Family

ID=64269934

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2019013714A MX2019013714A (es) 2017-05-16 2017-05-16 Metodos de tratamiento.
MX2021000609A MX2021000609A (es) 2017-05-16 2018-11-14 Métodos de tratamiento con fármacos sustrato para cyp3a4.
MX2022013410A MX2022013410A (es) 2017-05-16 2019-11-15 Metodos de tratamiento.
MX2025000380A MX2025000380A (es) 2017-05-16 2021-01-15 Metodos de tratamiento con farmacos del sustrato cyp3a4

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2021000609A MX2021000609A (es) 2017-05-16 2018-11-14 Métodos de tratamiento con fármacos sustrato para cyp3a4.
MX2022013410A MX2022013410A (es) 2017-05-16 2019-11-15 Metodos de tratamiento.
MX2025000380A MX2025000380A (es) 2017-05-16 2021-01-15 Metodos de tratamiento con farmacos del sustrato cyp3a4

Country Status (15)

Country Link
US (6) US10376507B2 (OSRAM)
EP (4) EP3426250B1 (OSRAM)
JP (7) JP2020520380A (OSRAM)
KR (3) KR20200010320A (OSRAM)
AU (10) AU2017414697B2 (OSRAM)
CA (1) CA3103793A1 (OSRAM)
DK (2) DK3426250T3 (OSRAM)
ES (2) ES2912373T3 (OSRAM)
FI (1) FI3716976T3 (OSRAM)
HR (1) HRP20220536T1 (OSRAM)
MX (4) MX2019013714A (OSRAM)
PL (1) PL3426250T3 (OSRAM)
SI (1) SI3426250T1 (OSRAM)
WO (2) WO2018212764A1 (OSRAM)
ZA (1) ZA202006746B (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6869988B2 (ja) 2015-12-23 2021-05-12 ニューロクライン バイオサイエンシーズ，インコーポレイテッド （Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法
MY199695A (en) * 2017-01-27 2023-11-18 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
US20220143011A1 (en) 2017-05-16 2022-05-12 Bow River LLC Methods of treatment with cyp3a4 substrate drugs
EP3426250B1 (en) * 2017-05-16 2022-03-23 Bow River LLC Treating a patient with a cyp3a4 substrate drug contraindicated for concomitant administration with a strong cyp3a4 inhibitor
WO2018226875A2 (en) * 2017-06-07 2018-12-13 University Of Kansas Methods and medicaments for the treatment of renal cell carcinoma
PT3684333T (pt) 2017-09-21 2025-05-08 Neurocrine Biosciences Inc Formulações e composições de valbenazina de alta dosagem, métodos, e kits relacionados com as mesmas
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CN109966298A (zh) * 2019-05-10 2019-07-05 辽宁大学 托伐普坦在制备降血脂药物中的应用
EP3980072A4 (en) * 2019-06-05 2023-06-14 University of Georgia Research Foundation COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED PULMONARY HYPERTENSION
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
EP4041922A4 (en) * 2019-10-07 2023-11-01 University Hospitals Cleveland Medical Center METHOD FOR TREATING WILD-TYPE ISOCITRATE DEHYDROGENASE-1 CANCER
EP4044192A4 (en) * 2019-11-15 2022-12-07 Cardio Intelligence Inc. METHOD, PROGRAM, DEVICE AND SYSTEM FOR FACILITATING THE DETERMINATION OF THE PHARMACEUTICAL FORM AND/OR DOSAGE OF A MEDICATION
WO2021118924A2 (en) 2019-12-12 2021-06-17 Ting Therapeutics Llc Compositions and methods for the prevention and treatment of hearing loss
CA3163321C (en) * 2020-04-01 2023-12-19 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments
US20230293534A1 (en) * 2020-07-24 2023-09-21 Secura Bio, Inc. Treatment of cancers using pi3 kinase isoform modulators
KR102601028B1 (ko) 2020-08-18 2023-11-10 재단법인대구경북과학기술원 아베마시클립을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
US20240041876A1 (en) * 2020-08-18 2024-02-08 Daegu Gyeongbuk Institute Of Science And Technology Pharmaceutical composition for prevention or treatment of degenerative brain diseases comprising abemaciclib as active ingredient
CN111920814B (zh) * 2020-09-04 2022-02-11 郑州大学 依匹哌唑在制备抗肿瘤药物中的应用
CN112898131B (zh) * 2020-11-05 2023-08-22 苏州凯祥生物科技有限公司 大麻二酚的提取工艺及大麻二酚或大麻提取物在制备预防或者治疗bph的药物中的应用
CN112206297B (zh) * 2020-11-16 2022-01-11 深圳市宝安区人民医院 治疗心脾两虚型失眠症的中药制剂及其制备方法
US11229644B1 (en) 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
EP4271381A4 (en) * 2020-12-31 2024-12-11 Lake O'Hara LLC METHODS OF TREATMENT OF PSYCHIATRIC DISORDERS WITH BREXPIPRAZOLE IN OBESE PATIENTS
CN112675175B (zh) * 2021-02-01 2022-11-01 天津济坤医药科技有限公司 布里格替尼在制备治疗特发性肺纤维化的药物中的应用
KR102843222B1 (ko) * 2021-11-30 2025-08-06 에스케이케미칼 주식회사 마이크로조말 트리글리세라이드 전달 단백질 억제제의 섬유화 질환 치료 용도
WO2023141634A2 (en) * 2022-01-24 2023-07-27 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
US20250302821A1 (en) * 2022-05-12 2025-10-02 St. Jude Children's Research Hospital, Inc. Synergistic antifungal composition and method
CN117045643A (zh) * 2023-09-26 2023-11-14 江苏百奥信康医药科技有限公司 一种cftr矫正剂在制备治疗乳腺增生症的药物中的应用
CN117982655B (zh) * 2023-11-21 2024-10-15 北京大学人民医院 芳香化酶抑制剂治疗相关的疼痛动物模型构建方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973970B2 (en) * 2000-08-09 2011-07-05 Ether Visuals Llc Preventing artifacts that may be produced when bottling PDL files converted from raster images
WO2007140299A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals
US7820681B1 (en) * 2009-01-14 2010-10-26 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
US7816383B1 (en) * 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US20140221424A1 (en) * 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
TW201628610A (zh) 2014-11-25 2016-08-16 奈諾生技公司 醫藥組合物、其製備及其用途
US10493024B2 (en) 2015-10-12 2019-12-03 Hk Tumescent Pharma Corporation Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
CN110167562A (zh) 2016-11-09 2019-08-23 萨恩帕斯药物有限公司 Dmpc、dmpg、dmpc/dmpg、lysopg和lysopc针对引起离子通道病的药物的保护作用
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
EP3426250B1 (en) 2017-05-16 2022-03-23 Bow River LLC Treating a patient with a cyp3a4 substrate drug contraindicated for concomitant administration with a strong cyp3a4 inhibitor

Also Published As

Publication number Publication date
AU2020203607B2 (en) 2020-07-09
AU2020250281A1 (en) 2020-11-05
MX2021000609A (es) 2021-06-23
EP3426250A4 (en) 2020-05-06
JP2020520380A (ja) 2020-07-09
AU2020203608A1 (en) 2020-06-25
JP6984024B2 (ja) 2021-12-17
JP7353343B2 (ja) 2023-09-29
AU2022228153B2 (en) 2025-04-24
US20180333411A1 (en) 2018-11-22
AU2020250281B2 (en) 2022-07-28
MX2025000380A (es) 2025-02-10
US20190255043A1 (en) 2019-08-22
AU2017414697A1 (en) 2019-11-07
US10835529B2 (en) 2020-11-17
EP3426250A1 (en) 2019-01-16
JP2022022264A (ja) 2022-02-03
CA3062770A1 (en) 2018-11-22
AU2022228153A1 (en) 2022-09-29
JP2025137510A (ja) 2025-09-19
AU2018432858A1 (en) 2021-01-07
AU2017414697B2 (en) 2020-03-05
ES2993832T3 (en) 2025-01-10
EP3716976A4 (en) 2021-02-17
MX2022013410A (es) 2022-11-14
ZA202006746B (en) 2023-03-29
SI3426250T1 (sl) 2022-09-30
JP2021510681A (ja) 2021-04-30
US20190076425A1 (en) 2019-03-14
AU2020203606A1 (en) 2020-06-25
JP2021059610A (ja) 2021-04-15
US11123346B2 (en) 2021-09-21
US20210154189A1 (en) 2021-05-27
AU2020202100A1 (en) 2020-04-09
ES2912373T3 (es) 2022-05-25
DK3716976T3 (da) 2024-10-28
JP7698009B2 (ja) 2025-06-24
AU2022204806B2 (en) 2025-04-24
EP4082546A1 (en) 2022-11-02
AU2018432858B2 (en) 2025-10-09
CA3103793A1 (en) 2020-01-23
WO2020018136A1 (en) 2020-01-23
AU2020202266A1 (en) 2020-04-23
AU2020203606B2 (en) 2020-07-09
JP2023021260A (ja) 2023-02-10
EP3426250B1 (en) 2022-03-23
AU2020203607A1 (en) 2020-06-25
PL3426250T3 (pl) 2022-08-08
EP4461298A3 (en) 2025-01-22
AU2020202266B2 (en) 2020-05-14
KR102805232B1 (ko) 2025-05-13
FI3716976T3 (fi) 2024-10-25
AU2022204806A1 (en) 2022-11-10
US20180333409A1 (en) 2018-11-22
US20180333410A1 (en) 2018-11-22
KR20200010320A (ko) 2020-01-30
EP4461298A2 (en) 2024-11-13
KR20210045400A (ko) 2021-04-26
WO2018212764A1 (en) 2018-11-22
EP3716976B1 (en) 2024-08-07
AU2020203608B2 (en) 2020-07-09
KR20210010663A (ko) 2021-01-27
US10376507B2 (en) 2019-08-13
EP3716976A1 (en) 2020-10-07
DK3426250T3 (da) 2022-05-16
AU2020202100B2 (en) 2020-07-02
HRP20220536T1 (hr) 2022-06-10
JP2023174661A (ja) 2023-12-08

Similar Documents

Publication Publication Date Title
MX2022013410A (es) Metodos de tratamiento.
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
MX2022005994A (es) Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras.
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
UY37581A (es) Compuestos para el tratamiento de la infección por virus de la hepatitis b
CR20170424A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsula del vhb
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX378872B (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
MX2019003703A (es) Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
MX2021014771A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv.
MX2018004132A (es) Método de tratamiento de meduloblastoma con un inhibidor de ezh2.
CY1121924T1 (el) Θεραπεια της λοιμωξης απο τον ιο της ηπατιτιδας δελτα
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX392470B (es) Composición farmacéutica que comprende un péptido wt1 para el tratamiento o prevención de una enfermedad angiogénica.
EA201691555A1 (ru) Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени
EA201992862A1 (ru) Назальные лекарственные формы дигидроэрготамина
MX2017009246A (es) Farmaco de combinacion.
FI3661510T3 (fi) Menetelmiä käyttäytymismuutosten hoitamiseksi
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
WO2016090107A3 (en) Treatment of hepatitis delta virus infection
MX2019013014A (es) Tratamiento de carcinoma hepatocelular.
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof
MX2018002681A (es) Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1".
EA201790220A1 (ru) Лечение симптомов, связанных с андроген-депривационной терапией